Repros Therapeutics Inc. Provides Update For Ongoing Clinical Studies

THE WOODLANDS, Texas--(BUSINESS WIRE)--May 22, 2006--Repros Therapeutics, Inc. (Nasdaq:RPRX - News; PCX:RPRX - News) today provided an update regarding the progress of its three ongoing clinical studies. The studies include a 200 patient US Phase III study of Androxal(TM) for the treatment of testosterone deficiency in men with secondary hypogonadism, a 150 patient US Phase II study of Proellex(TM) in the treatment of uterine fibroids and a 40 patient European Phase II study of Proellex(TM) in the treatment of endometriosis. All three studies have been contracted to Pharm Olam International (POI), the contract research organization (CRO), to conduct the trials.